A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Aim: Functional food and their bioactive compounds have been considered as a new approach for the prevention and management of type 2 diabetes and its complications. According to this approach current study was carried out as an elucidation of antidiabetic properties of Corchorus capsularis and Corchorus olitorius varieties of jute leaf (ethanolic extract) on nSTZ-induced type-2 diabetic rats. Methodology: The type-2 diabetic model rat was developed by a single intraperitoneal injection of freshly prepared STZ (90 mg/kg/10 ml) in sterile citrate buffer (0.1 M, pH 4.5) to rat pups (48 hour old). After three months, OGTT was performed to select diabetic (FSG > 6.5mmol/L and after 90 min of glucose load > 14 mmol/L) experimental rats. The rats were randomly divided into four groups [DWC, GT, Ext-1 and Ext-2 represent, diabetic water control, glybenclamide treated (20 mg/5 ml/kg body weight), C. capsularis treated and C. olitorius treated group (1.25 g/10 ml/kg body weight) respectively]. One group was kept with normal rats [normal water control, NWC]. The treatment was given once daily or 28 consecutive days. Fasting serum glucose, liver glycogen and lipid profile were estimated by using standard methods. Results: The results showed that Ext-1 and Ext-2 treated groups gradually decreased serum glucose level (7.15 ±0.67 to 5.94 ± 1.19 and 7.20 ± 0.93 to 5.28 ±1.03 respectively) and reducing effect by Ext-2 was significant (p=0.001). Both extract showed lower liver glycogen level compared with GT group [5.0±2.5 Vs 17.7±6.5 (Ext-1 vs GT) and 7.5±6.4 Vs 17.7±6.5 (Ext-2 vs GT)] and even Ext-1 manifested significant effect (p=0.05). Additionally, lipid profile estimation revealed no significant improvement by the consumption of both the extracts. Conclusion: On the basis of current investigations, it may be concluded that both variety of jute’s leaf demonstrated hypoglycemic properties in Type 2 diabetic model rats; further in-depth studies are recommended to explore the exact mechanism(s) of hypoglycemic effect.

Download Full-text

The effect of different antihypertensive treatment protocoles on glycemic control and lipid profile in type 2 diabetic patients with microalbuminuria and stage 1 hypertension

Endocrine Abstracts ◽

10.1530/endoabs.49.ep533 ◽

2017 ◽

Author(s):

Muge Erek ◽

Alparslan Ersoy ◽

Canan Ersoy

Keyword(s):

Glycemic Control ◽

Lipid Profile ◽

Antihypertensive Treatment ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Stage 1 ◽

Type 2 Diabetic

Download Full-text

Molecular Genetic Investigation of ANGPTL8 Gene in Type 2 Diabetic Patients and Its Relationship with Some Serum Lipid Profile.

International Journal of Pharmaceutical Research ◽

10.31838/ijpr/2019.11.02.076 ◽

2019 ◽

Vol 11 (02) ◽

Keyword(s):

Lipid Profile ◽

Serum Lipid ◽

Molecular Genetic ◽

Serum Lipid Profile ◽

Diabetic Patients ◽

Genetic Investigation ◽

Type 2 Diabetic Patients ◽

Type 2 Diabetic

Download Full-text

Lipid profile in type 2 diabetic subjects aged 40 years and over living in Benin

International Journal of Biomedical Research ◽

10.7439/ijbr.v6i10.2617 ◽

2015 ◽

Vol 6 (10) ◽

pp. 805

Author(s):

Casimir D. Akpovi ◽

Segbo A.G. Julien ◽

Medehouenou T.C. Marc ◽

Anago A.A. Eugénie ◽

Akakpo B. Huguette ◽

...

Keyword(s):

Lipid Profile ◽

Type 2 Diabetic

Download Full-text

Effect of atorvastatin on oxidative stress parameters and lipid profile in type 2 diabetic patients

IIUM Medical Journal Malaysia ◽

10.31436/imjm.v7i2.783 ◽

2020 ◽

Vol 7 (2) ◽

Author(s):

Najah RH ◽

Mohammad AAH ◽

Ammar RMR

Keyword(s):

Oxidative Stress ◽

Lipid Profile ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Oxidative Stress Parameters ◽

Type 2 Diabetic ◽

Stress Parameters

Introduction: Evidence has long existed regarding the relationship between oxidative stress and diabetes. The present study was conducted to assess the effect of atorvastatin on selected oxidative stress parameters in the form of reduced glutathione (GSH), lipid peroxidation byproduct malondialdehyde (MDA) levels, glutathione –S- transferase (GST) activity and catalase (CAT) activity) and its effect on lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in dyslipidaemic type 2 diabetic patients . Materials and Methods: Fifty nine dyslipidaemic type 2 diabetic patients were included in this study. Full history was taken and general examination of patients was performed. Patients studied were taking glibenclamide (an oral hypoglycaemic drug) during the study as a treatment for their disease. These patients were followed up for 60 days and divided randomly into 2 groups. Group I (n = 31): no drug was given and served as dyslipidaemic diabetic control. Group II (n = 28): received atorvastatin tablets 20 mg once daily at night. Of the 59 Fifty patients, 46 completed the study while 13 patients withdrew. This is due to non compliance of the patients. Blood samples were drawn from the patients at the beginning and after 60 days of follow up between 8:30 & 10:30 am after at least 12-14 hours fast. Fasting blood glucose, lipid profile, selected oxidative stress parameters (GSH, MDA levels, GST and CAT activities) were measured. Renal and hepatic functions were also assessed. Results: This study revealed that: atorvastatin treatment increased serum GSH; reduced MDA levels significantly while did not significantly affect CAT and GST activity. In atorvastatin treatment, TC, TG, LDL and VLDL decreased significantly while HDL increased significantly. Conclusion: There was insignificant correlations between atorvastatin induced changes in the oxidation markers and the observed changes of the lipid profile.

Download Full-text

EFFECT OF ALOE BARBADENSIS MILLER WHOLE LEAF EXTRACT ON HYPERGLYCEMIA AND INSULIN RESISTANCE IN LOW DOSE STREPTOZOTOCIN INDUCED TYPE 2 DIABETIC RATS

Journal of Saidu Medical College, Swat ◽

10.52206/jsmc.2013.3.2.350-355 ◽

1969 ◽

Vol 3 (2) ◽

pp. 350-355

Author(s):

MEENA GUL ◽

MUHAMMAD MAZHAR HUSSAIN ◽

AYESHA BABER ◽

AMJAD ZAMAN ◽

MUSRAT ZAHRA

Keyword(s):

Insulin Resistance ◽

Body Weight ◽

Plasma Glucose ◽

Leaf Extract ◽

Low Dose ◽

Aloe Vera ◽

Control Group ◽

Sprague Dawley ◽

Type 2 Diabetic

BACKGROUND: Managing diabetes is difficult due to the number of side effects associated with drugsused for its treatment. There it is a need of an hour to look for indigenous plants which are safe and costeffective. Present study was planned to determine the effect of Aloe vera whole leaf extract and/orRosiglitazone on plasma glucose, insulin and insulin resistance in type 2 diabetic Sprague-Dawley rats.DESIGN: Randomized control trailPLACE AND DURATION OF STUDY: This study was conducted from April 2009 to Oct 2010 at theDepartment of Physiology Army Medical College, Rawalpindi in collaboration with National Institute ofHealth (NIH) Islamabad.MATERIAL AND METHOD: Type 2 DM was induced in 60 healthy Sprague-Dawley rats by feedinghigh fat diet for 2 weeks and injecting a low dose (35mg/kg) of streptozotocin intra peritoneally. Type 2diabetic rats were randomly divided into four groups, each group having 15 rats and were labeled as diabeticgroup, Aloe vera group, rosiglitazone group and combined group. The diabetic group was injected normalsaline, Aloe vera group was treated with Aloe vera whole leaf extract in dose of 300mg/kg body weight,rosiglitazone group was given 5mg/kg body weight of rosiglitazone I/P and combined group diabetic ratswere treated with 150mg/kg body weight of Aloevera extract and 2.5mg/kg body weight of rosiglitazone(halfof their effective dose) for 21 days.RESULTS: A significant reduction (p<0.001) in plasma glucose (73%), insulin (32%) and TG/HDL ratio(81%) was analyzed in combined groupascompared to diabetic control group. \CONCLUSION: The maximum impact in lowering plasma glucose, insulin and TG/HDL ratio wasrecorded in combined group, followed by rosiglitazone group and then Aloevera group.KEYWORDS:T2DM. Aloe vera, insulin resistance

Download Full-text

The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities

Problems of Endocrinology ◽

10.14341/probl201258351-55 ◽

2012 ◽

Vol 58 (3) ◽

pp. 51-55

Author(s):

E N Ostroukhova ◽

O K Khmel'nitskiĭ ◽

E I Krasil'nikova ◽

K S Davidenko

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Body Weight ◽

Adverse Reactions ◽

Brand Name ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Acting

This paper reports the results of the treatment of 71 patients presenting with type 2 diabetes mellitus using liraglutide, a long-acting analog of glucagon-like peptide-1 (GLP-1) marketed under the brand name Victoza. Practically all the patients experienced either improvement or normalization of the parameters of carbohydrate metabolism in conjunction with a reduction of their body weight and arterial pressure. There were no severe hypoglycemic episodes and other adverse reactions to the therapy. It is recommended that Victoza should be more widely used for the treatment of the patients with type 2 diabetes mellitus.

Download Full-text

A controlled study of consumption of β-glucan-enriched soups for 2 months by type 2 diabetic free-living subjects

British Journal Of Nutrition ◽

10.1017/s0007114509991875 ◽

2009 ◽

Vol 103 (3) ◽

pp. 422-428 ◽

Cited By ~ 48

Author(s):

Christine Cugnet-Anceau ◽

Julie-Anne Nazare ◽

Maria Biorklund ◽

Elodie Le Coquil ◽

Agnès Sassolas ◽

...

Keyword(s):

Lipid Profile ◽

Glucose Control ◽

Dietary Intervention ◽

Fasting Glucose ◽

Controlled Study ◽

Control Group ◽

Free Living ◽

Apo B ◽

Type 2 Diabetic

Type 2 diabetes is associated with a higher cardiovascular risk and there has been a growing interest in using dietary intervention to improve lipid profile and glucose control. The present work aims at analysing the effects of the enrichment of a normal diet with β-glucan (3·5 g/d) in free-living type 2 diabetic subjects for 2 months, using a palatable soup. This trial was a parallel, placebo-controlled, double-blinded randomised study performed in fifty-three type 2 diabetic subjects. During a 3-week run-in period, subjects daily consumed a ready meal control soup (without β-glucan). For the following 8 weeks, subjects were randomly assigned to consume daily either a control soup or a β-glucan soup. Changes in lipid profile (total cholesterol (TC), HDL- and LDL-cholesterol (HDLc and LDLc), apo B and TAG) and in glucose control (HbA1c and fasting glucose) were measured. There was no significant alteration in lipid profile in the two groups (TC, HDLc, LDLc and apo B). TAG decreased significantly in the β-glucan group compared with the control group ( − 0·12 (sd0·38)v. 0·12 (sd0·44) mmol/l,P = 0·03). HbA1c and fasting glucose were not reduced in any group. A single daily ingestion of 3·5 g β-glucan, as required by official dietary recommendations, for 8 weeks did not change the lipid profile and HbA1c in type 2 diabetic subjects. To improve the metabolic profile of type 2 diabetic subjects in the long term, the quantity, the food vectors and the tolerability of β-glucan products may be re-evaluated.

Download Full-text